Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2021/07/035113
CTRI/2021/07/035113
Not yet recruiting
未知

COMPARATIVE STUDY OF SAFETY AND EFFICACY OF THREE DIFFERENT DOSES OF FENTANYL ON HEMODYNAMIC RESPONSE TO LARYNGOSCOPY AND TRACHEAL INTUBATION IN PATIENTSâ?? UNDER GENERAL ANAETHESIA.

DEPARTMENT OF ANESTHESIOLOGY0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
DEPARTMENT OF ANESTHESIOLOGY
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. American Society of Anaethesiology (ASA) grade I and II
  • •2\. Patients posted for elective surgery under GA requiring endotracheal intubation.
  • •3\.Hemodynamically stable patients with all routine investigationswithin normal limits.
  • •4\. Availability of informed consent.

Exclusion Criteria

  • •1\.Patients with ASA physical status III or more.
  • •2\. Patients with major neurological, cardiac, respiratory, metabolic, renal, hepatic disease or with coagulation abnormalities.
  • •3\. Patients with anticipated difficult intubation.
  • •4\. Patients with known allergies to the study drug.
  • •5\. Patients who are not giving consent for above study.
  • •6 .Patients with body mask index more than 30\.
  • •7\.Patients posted for emergency procedure.
  • •8\. Pregnant patients.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKSPatients with papulo-pustular rosaceaMedDRA version: 9.0Level: LLTClassification code 10039218
EUCTR2006-001999-20-CZGalderma Research & Development SNC270
Active, not recruiting
Not Applicable
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKS
EUCTR2006-001999-20-HUGalderma Research & Development SNC270
Active, not recruiting
Not Applicable
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKSPatients with papulo-pustular rosaceaMedDRA version: 9.0Level: LLTClassification code 10039218
EUCTR2006-001999-20-DEGalderma Research & Development SNC274
Not yet recruiting
Phase 2
Evaluation and comparison of the efficacy of triple therapies regimens containing esomeprazole and different doses of amoxicillin and bismuth for eradicating Helicobacter pylori infection in Sari
IRCT20210518051335N1Mazandaran University of Medical Sciences200
Completed
Not Applicable
The study on the effectiveness of three Protecting on the infantile colic paiColic in infants.Other and unspecified abdominal pain
IRCT2017102514333N84Vice chancellor for research, Esfahan University of Medical Sciences100